Skin developer to start ulcer trial:
This article was originally published in Clinica
Artificial skin developer Ortec International will begin early trials of its Composite Culture Skin (CCS) in September for treating venous ulcers. Subject to internal review board approval, the pilot trial will study up to 40 patients and follow them for six months after wound closure. New York-based Ortec then plans to begin a major FDA-approved trial in the first quarter of 2000. CCS is made from bovine collagen which is seeded with dermal and epidermal skin cells.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.